Online inquiry

IVTScrip™ mRNA-Anti-RTN4, 6A3-IgG4(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ588MR)

This product GTTS-WQ588MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets RTN4 gene. The antibody can be applied in Spinal cord injury research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001321859.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 57142
UniProt ID Q9NQC3
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-RTN4, 6A3-IgG4(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ588MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4459MR IVTScrip™ mRNA-Anti-SLAMF7, BMS-901608(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA BMS-901608
GTTS-WQ13209MR IVTScrip™ mRNA-Anti-PCSK9, PF-04950615(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA PF-04950615
GTTS-WQ14719MR IVTScrip™ mRNA-Anti-SELP, SEG101(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA SEG101
GTTS-WQ5327MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, CD20-TCB (2:1)(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CD20-TCB (2:1)
GTTS-WQ6893MR IVTScrip™ mRNA-Anti-CX3CL1, E-6011(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA E-6011
GTTS-WQ5406MR IVTScrip™ mRNA-Anti-CD2, CD58-Fc(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA CD58-Fc
GTTS-WQ10111MR IVTScrip™ mRNA-Anti-MET, LA480(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA LA480
GTTS-WQ13517MR IVTScrip™ mRNA-Anti-SNCA, PRX002(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA PRX002
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW